Welcome to our dedicated page for Quanterix news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix stock.
Quanterix Corporation (NASDAQ: QTRX) generates news that spans scientific breakthroughs, clinical research, corporate developments, and financial performance, all centered on its ultra-sensitive Simoa biomarker detection technology and spatial biology capabilities. As a life sciences company active in testing laboratories and professional scientific services, Quanterix regularly reports on studies, collaborations, and product launches that affect disease research and diagnostics.
Investors and researchers following QTRX news will see coverage of peer‑reviewed studies that rely on Simoa assays, such as large population-based analyses of Alzheimer’s Disease Neuropathological Changes using p‑Tau 217, and multiple sclerosis research that combines GFAP and NfL biomarkers for personalized monitoring. These articles illustrate how Quanterix assays and reference databases are applied in real-world clinical and epidemiological settings.
The company also issues updates on new assay launches and platform enhancements, including commercial introductions of p‑Tau 205 and p‑Tau 212 assays for Alzheimer’s research, and developments at the Quanterix Accelerator Laboratory, which supports clinical testing and global clinical trials. News items may highlight regulatory milestones, such as clinical laboratory permits and medical device registrations for specific assay kits in various markets.
From a corporate and capital markets perspective, Quanterix news includes quarterly financial results, non‑GAAP performance metrics, and commentary on integration progress following its acquisition of Akoya Biosciences. Filings and press releases discuss cost synergies, revenue composition across product and service lines, and governance changes such as cooperation agreements with shareholders and Board structure updates.
This QTRX news page brings together these updates so readers can track scientific publications, diagnostic advancements, spatial biology integration, and financial disclosures in one place.
Quanterix Corporation (NASDAQ: QTRX) reported expected Q4 2021 revenue between $29-31 million and full-year revenue between $109-111 million. Noteworthy Q4 growth includes product and service revenue expected at $28-30 million, representing 35% growth year-over-year. For the full year, product revenue is projected at $80-82 million, an 84% increase. The company is advancing precision health with its biomarker detection technology, receiving FDA Breakthrough Device Designation for its Alzheimer’s test.
Quanterix Corporation (NASDAQ: QTRX) announced that its Chairman and CEO, Kevin Hrusovsky, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022, at 8:15 a.m. EST. This marks Hrusovsky's sixth consecutive year presenting at the conference, where he will discuss the company's growth and vision. Additionally, he will host one-on-one meetings with institutional investors. Investors can access the live webcast of the presentation at Quanterix's conference webpage. The company's technology aims to enhance precision health through advanced biomarker analysis.
Summary not available.
Quanterix Corporation (NASDAQ: QTRX) announced advancements in Alzheimer's disease clinical trials utilizing its ultra-sensitive Simoa® technology. Findings presented at the CTAD conference from November 9-12, 2021, underscored the importance of plasma biomarkers like pTau-181 and pTau-217 in early-stage patient trials, enhancing enrollment efficiency. Biogen and Eli Lilly showcased significant correlations between plasma biomarker reductions and cognitive decline in their studies. Additionally, Simoa's pTau-181 assay received FDA Breakthrough Device Designation, marking a notable achievement for Quanterix.
Quanterix Corporation (NASDAQ: QTRX) will participate in a virtual fireside chat at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Nov. 18 at 8:30 a.m. EST. Executives including CEO Kevin Hrusovsky and CFO Mike Doyle will discuss advancements in biomarker analysis for precision health. A live webcast will be available on their investor relations site, with replays for 90 days post-event. Quanterix's Simoa technology aims to enhance early disease detection and improve patient care across several therapeutic areas.
Quanterix Corporation (NASDAQ: QTRX) reported Q3 2021 total revenue of $27.7M, down 12% year-over-year, primarily due to a prior year one-time license revenue of $11.2M. Non-GAAP total revenue increased 46% to $26.7M. Product revenue surged 77% to $20.7M, driven by a 98% rise in consumables and 44% in instruments. The gross margin decreased to 55.1% from 67.2% due to rising costs. Key advancements included FDA Breakthrough Device designation for the pTau-181 blood test and expanded EUA for the SARS-CoV-2 test. The company aims to enhance precision health diagnostics.
Quanterix Corporation (NASDAQ: QTRX) announced it will release its third quarter 2021 financial results on November 4, 2021, after market close. A conference call hosted by CEO Kevin Hrusovsky will follow at 4:30 p.m. EDT to discuss the results and provide a business update. Interested parties can join the call via phone or livestream. Quanterix aims to digitize biomarker analysis to enhance precision health, focusing on earlier disease detection and improved treatment methods across various therapeutic areas.
Quanterix Corporation (NASDAQ: QTRX) announced that its Simoa® phospho-Tau 181 blood test has received Breakthrough Device designation from the FDA for aiding in the diagnostic evaluation of Alzheimer’s Disease. This designation supports faster development and review processes, aiming for earlier, non-invasive diagnosis of the disease. The test is intended for adult patients over 50 with cognitive impairment and is not a standalone diagnostic tool. The Breakthrough Device designation reflects Quanterix's commitment to advancing precision health through innovative diagnostics.
Quanterix Corporation (NASDAQ: QTRX) hosted a webinar on September 16, 2021, discussing ultra-sensitive COVID-19 detection for asymptomatic individuals. The event featured Kevin Hrusovsky and pathologist Dr. John Roback, highlighting Emory University’s effective SARS-CoV-2 screening program, which has tested over 120,000 samples. The webinar emphasized the importance of Simoa technology in advancing preventative medicine, particularly in infectious diseases and other health areas. The recording is available on Quanterix’s website.
Quanterix Corporation (NASDAQ: QTRX) announced the expansion of the Emergency Use Authorization (EUA) for its Simoa SARS-CoV-2 N Protein Antigen Test. This test is now authorized for use with nasal swab and saliva samples, making it the first antigen test approved for saliva. The test is validated against all CDC-designated Variants of Concern, including the Delta variant. This expansion aims to enhance less-invasive testing options and improve SARS-CoV-2 testing capacity across the U.S.